



ZIOPHARM Oncology, Inc.
Investor Relations Department
One First Ave., Parris Building, # 34
Navy Yard Plaza
Boston, MA 02199
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ZIOP

Last Trade:	4.57
Trade Time:	4:00 PM ET Nov 17, 2017
Change:	-0.17 (-3.586%)
Day Range	4.40 - 4.83
52-Week Range	4.04 - 7.88
Volume	2,692,654


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

ZIOPHARM Oncology, Inc. is a biopharmaceutical company that is seeking to develop and commercialize a diverse portfolio of treatments for people with cancer and graft-versus-host -disease. Our focus is on the development of cell and viral -therapies using a suite of technologies that employing novel gene expression, control and cell technologies to deliver safe, effective and scalable therapies.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Nov 17, 2017
[ZIOPHARM Oncology to Host Conference Call on November 20, 2017 at 10:15 a.m. ET to Discuss Updated Clinical Data Presented at the 2017 Annual Meeting of the Society for Neuro-Oncology](#)
- Nov 10, 2017
[ZIOPHARM to Present at the Stifel 2017 Healthcare Conference](#)
- Nov 6, 2017
[ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities](#)
- Nov 6, 2017
[ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology](#)
- Nov 1, 2017
[ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting](#)

Upcoming Events [\[View all \]](#)

- Nov 20, 2017 10:15 AM ET
[Ziopharm 2017 SNO Update Call](#)
- Feb 16, 2017
[Annual Report \(10-K\)](#)
- Apr 28, 2017
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017
[Quarterly Report \(10-Q\)](#)
- Jul 31, 2017
[Quarterly Report \(10-Q\)](#)
- May 1, 2017
[Quarterly Report \(10-Q\)](#)

Financials [\[View all \]](#)